sur Jaguar Health, Inc. (NASDAQ:JAGX)
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Jaguar Health, Inc. has announced that Jordan's Industrial Property Protection Directorate has issued a new patent to its subsidiary Napo Pharmaceuticals for methods treating short bowel syndrome (SBS) and other related conditions. This patent enhances the protection of crofelemer, Jaguar's plant-based prescription drug.
Jaguar currently holds approximately 230 patents issued and pending. The company is also supporting proof-of-concept studies of crofelemer for SBS and microvillus inclusion disease (MVID) in various regions, with results expected by the end of 2024 and throughout 2025.
Some SBS patients face intestinal failure, requiring intensive parenteral nutrition (PN). MVID is a severe condition characterized by infantile diarrhea and requires significant nutritional and fluid management due to the lack of approved drug treatments.
Jaguar and Napo prioritize intellectual property protection to bolster their portfolio. Crofelemer remains the sole oral plant-based prescription medicine approved by the FDA under its Botanical Guidance, providing an exclusivity advantage.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Jaguar Health, Inc.